Alto Neuroscience Statistics
Total Valuation
ANRO has a market cap or net worth of $742.94 million. The enterprise value is $502.39 million.
| Market Cap | 742.94M |
| Enterprise Value | 502.39M |
Important Dates
The last earnings date was Wednesday, May 13, 2026, before market open.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ANRO has 35.09 million shares outstanding. The number of shares has increased by 12.42% in one year.
| Current Share Class | 35.09M |
| Shares Outstanding | 35.09M |
| Shares Change (YoY) | +12.42% |
| Shares Change (QoQ) | -3.77% |
| Owned by Insiders (%) | 2.65% |
| Owned by Institutions (%) | 54.06% |
| Float | 23.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.05 |
| P/TBV Ratio | 3.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.52, with a Debt / Equity ratio of 0.10.
| Current Ratio | 20.52 |
| Quick Ratio | 20.11 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -32.21 |
Financial Efficiency
Return on equity (ROE) is -38.86% and return on invested capital (ROIC) is -22.51%.
| Return on Equity (ROE) | -38.86% |
| Return on Assets (ROA) | -21.71% |
| Return on Invested Capital (ROIC) | -22.51% |
| Return on Capital Employed (ROCE) | -29.58% |
| Weighted Average Cost of Capital (WACC) | 11.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.09M |
| Employee Count | 68 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +778.42% in the last 52 weeks. The beta is 1.25, so ANRO's price volatility has been higher than the market average.
| Beta (5Y) | 1.25 |
| 52-Week Price Change | +778.42% |
| 50-Day Moving Average | 22.88 |
| 200-Day Moving Average | 16.07 |
| Relative Strength Index (RSI) | 50.15 |
| Average Volume (20 Days) | 342,397 |
Short Selling Information
The latest short interest is 1.69 million, so 4.82% of the outstanding shares have been sold short.
| Short Interest | 1.69M |
| Short Previous Month | 1.59M |
| Short % of Shares Out | 4.82% |
| Short % of Float | 7.15% |
| Short Ratio (days to cover) | 5.31 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -77.83M |
| Pretax Income | -74.31M |
| Net Income | -74.31M |
| EBITDA | -77.15M |
| EBIT | -77.83M |
| Earnings Per Share (EPS) | -$2.45 |
Balance Sheet
The company has $263.76 million in cash and $23.22 million in debt, with a net cash position of $240.55 million or $6.85 per share.
| Cash & Cash Equivalents | 263.76M |
| Total Debt | 23.22M |
| Net Cash | 240.55M |
| Net Cash Per Share | $6.85 |
| Equity (Book Value) | 243.37M |
| Book Value Per Share | 6.94 |
| Working Capital | 256.01M |
Cash Flow
In the last 12 months, operating cash flow was -$62.30 million and capital expenditures -$556,000, giving a free cash flow of -$62.86 million.
| Operating Cash Flow | -62.30M |
| Capital Expenditures | -556,000 |
| Depreciation & Amortization | 674,000 |
| Net Borrowing | 750,000 |
| Free Cash Flow | -62.86M |
| FCF Per Share | -$1.79 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ANRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.42% |
| Shareholder Yield | -12.42% |
| Earnings Yield | -10.00% |
| FCF Yield | -8.46% |
Analyst Forecast
The average price target for ANRO is $35.13, which is 65.94% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.13 |
| Price Target Difference | 65.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |